| Therapeutic | Secukinumab |
| Target | IL17A |
| Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSS |
| Light Chain | EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIK |
| 100% seqID Fv Structure | 6wio [Fvs: AB], 6wir [Fvs: AB] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 6wio [Fvs: AB] |
| 100% seqID Structure | 6wir [Fvs: AB] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G1 |
| Highest Clinical Trial (Aug '24) | Approved |
| Estimated Status (Aug '24) | Active |
| Recorded Developmental Technology | Abgenix XenoMouse |
| INN Year Proposed | 2009 |
| INN Year Recommended | 2010 |
| Companies Involved | Beth Israel Deaconess Medical Center, GWT-TUD GmbH, Icahn School of Medicine at Mount Sinai, Novartis, Alcon |
| Conditions Approved | Ankylosing spondylitis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis |
| Conditions Active | Hidradenitis suppurativa, Juvenile rheumatoid arthritis, Non-radiographic axial spondyloarthritis, Rheumatoid arthritis, Alopecia areata, Atopic dermatitis, Giant cell arteritis, Necrobiosis lipoidica, Tendon injuries |
| Conditions Discontinued | Asthma, Crohn's disease, Dry eyes, Multiple sclerosis, Polymyalgia rheumatica, Type 1 diabetes mellitus, Uveitis |
| Notes | Biosimilars available |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
